ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2010
Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- A New Method for Chromosomes Preparation by ATP-Competitive Inhibitor SP600125Frontiers in bioengineering and biotechnology · 2020Article
- MAD2 Combined with Mitotic Spindle Apparatus (MSA) and Anticentromere Antibody (ACA) for Diagnosis of Small Cell Lung Cancer (SCLC).Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.Oncotarget · 2017Article
- MAD2γ, a novel MAD2 isoform, reduces mitotic arrest and is associated with resistance in testicular germ cell tumors.Cell cycle (Georgetown, Tex.) · 2016Article
- Helicobacter pylori infection and gastric carcinoma: Not all the strains and patients are alike.World journal of gastrointestinal oncology · 2016Review
- Multidrug-Resistance Related Long Non-Coding RNA Expression Profile Analysis of Gastric Cancer.PloS one · 2015Article
- Disruption of FAT10-MAD2 binding inhibits tumor progression.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Mad2 checkpoint gene silencing using epidermal growth factor receptor-targeted chitosan nanoparticles in non-small cell lung cancer model.Molecular pharmaceutics · 2014Article
- Microarray analysis of cell cycle gene expression in adult human corneal endothelial cells.PloS one · 2014Article
- Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.Acta pharmacologica Sinica · 2013Article
- Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.The Journal of pathology · 2012Article
- Genome-wide profiling of pluripotent cells reveals a unique molecular signature of human embryonic germ cells.PloS one · 2012Article
- Genetic aspects of gastric cancer instability.TheScientificWorldJournal · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitotic arrest-deficient 2 (MAD2) is one of the essential mitotic spindle checkpoint regulators, and it can protect cells from aberrant chromosome segregation. The Mad2 gene is very rarely mutated in many kinds of human cancer, but aberrantly reduced expression of MAD2 has been correlated with defective mitotic checkpoints in several human cancers. We have previously found that the MAD2 expression level is also shown to be associated with the multidrug resistance of tumour cells. In this study, we constructed a small interfering RNA (siRNA) eukaryotic expression vector of MAD2 and downregulated MAD2 expression in the gastric cancer cell line SGC7901 by transfection of MAD2-siRNA. SGC7901 cells stably transfected with the MAD2-siRNA exhibited significantly increased expression of phosphorylated survivin protein and enhanced drug resistance. Furthermore, MAD2-siRNA suppressed the proliferation of SGC7901 cells and inhibited tumour formation in athymic nude mice. This study clearly reveals that downregulation of MAD2 could regulate the cell cycle, increase proliferation, and improve the drug resistance of gastric cancer cells by regulating the activation of phosphorylated survivin. It also suggests both that MAD2 might play an important role in the development of human gastric cancer and that silencing the MAD2 gene may help to deal with the multidrug resistance of gastric cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.